UCB SA (OTCMKTS:UCBJY) Short Interest Up 10,342.9% in October

UCB SA (OTCMKTS:UCBJY) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 73,100 shares, a growth of 10,342.9% from the September 30th total of 700 shares. Based on an average trading volume of 53,900 shares, the short-interest ratio is presently 1.4 days.

UCB Trading Up 2.0 %

Shares of OTCMKTS:UCBJY traded up $1.91 during midday trading on Friday, reaching $95.55. 19,695 shares of the company were exchanged, compared to its average volume of 18,184. The stock has a fifty day simple moving average of $90.93 and a two-hundred day simple moving average of $78.90. UCB has a fifty-two week low of $34.85 and a fifty-two week high of $95.81.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.